Phase I, open label, dose escalation with expansion study to evaluate the safety and tolerability of INC280 in patients with advanced solid tumors dependent on C-MET
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: I
- Execution start: 09/12/2014
- End of execution: 30/03/2016
- IP: JUAN RAMON DELGADO PEREZ